Endocyte Provides First Quarter 2018 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
52
Endocyte Provides First Quarter 2018 Financial Results and Operational Update

-Recently Updated Phase 2 Data on 177 Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress-

       -Positive End of Phase 2 FDA Meeting Set Stage for Successful Financing in First Quarter-

               -Phase 3 VISION Trial on Track for First Patient Visit in Q2 2018-

-Conference Call Today at 8:30 a.m. EDT-

WEST LAFAYETTE, Ind., May 09, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT ), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced financial results for the first quarter ending Mar. 31, 2018 and provided an operational update.

“We made important progress during the first quarter in establishing the design of our phase 3 VISION trial of 177 Lu-PSMA-617, securing clinical supply of no-carrier-added Lutetium, and raising sufficient capital to fund the company through expected completion of the trial,” said Mike Sherman, president and CEO of Endocyte. “We continue to expect the first patient visit in the VISION trial in the second quarter and are working to advance EC17/CAR T-cell therapy, our folate-targeted CAM-based therapy, for which we expect to have an IND submitted in the fourth quarter of 2018.”

Mr. Sherman continued, “In addition, we are encouraged by the updated 30 patient data from the ongoing phase 2 trial at Peter MacCallum Cancer Centre in Melbourne, Australia, published today in The Lancet Oncology . We anticipate an update at the American Society of Clinical Oncology Annual Meeting in June with early data on the additional 20 patients dosed in the expansion phase of that trial. Enrollment also continues in the phase 2 TheraP trial in Australia comparing 177 Lu-PSMA-617 to cabazitaxel in 200 patients.”

First Quarter and Recent Highlights

  • Finalized the design for the phase 3 VISION trial evaluating 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration.
  • Announced an agreement with ITM Isotopen Technologien München AG to supply no-carrier-added Lutetium ( 177 Lu) to support the phase 3 VISION trial.
  • Presented data on the chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM) platform at the American Association for Cancer Research Annual Meeting 2018 confirming the anti-tumor activity of Endocyte’s folate-targeted EC17/CAR T-cell therapy.
  • Completed an underwritten registered public offering of 20,535,714 shares of its common stock, including full exercise of the underwriters’ option to purchase additional shares of common stock, at a public offering price of $4.20 per share. Endocyte received aggregate net proceeds from the offering of approximately $80.9 million.
  • Hired additional experienced clinical trial professionals to ensure strong execution and support the success of its clinical programs.
  • Elected Patrick Machado, J.D., co-founder and former chief business and financial officer of Medivation, and Dawn Svoronos, former president of Merck’s Europe/Canada region, to serve on the Board of Directors, bringing significant commercial leadership and understanding of the prostate cancer market to the Board.

Expected 2018 Milestones

  • First patient visit for phase 3 VISION trial of 177 Lu-PSMA-617 in mCRPC (2Q 2018).
  • 50-patient response rate data readout of investigator-initiated trial of 177 Lu-PSMA-617 in mCRPC patients at Peter MacCallum Cancer Centre in Melbourne, Australia, to be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO)  (June 2018).
  • Publications on additional ongoing investigator-initiated clinical trials of 177 Lu-PSMA-617 in prostate cancer patients (2018).
  • IND for phase 1 trial of EC17/CAR T-cell therapy in patients with osteosarcoma (4Q 2018).

First Quarter 2018 Financial Results

Endocyte reported a net loss of $8.6 million, or $0.16 per basic and diluted share, for the first quarter of 2018, compared to a net loss of $11.5 million, or $0.27 per basic and diluted share for the same period in 2017.

Research and development expenses were $5.3 million for the first quarter of 2018, compared to $8.0 million for the same period in 2017. The decrease was primarily attributable to a strategic portfolio review announced in June 2017 which led to a reduction in workforce and the discontinuation of certain research and development activities, including: a decrease of $1.4 million in expenses related to pre-clinical work and general research, including the development of EC2629; a decrease of $0.8 million in EC1169 trial expenses; a decrease of $0.6 million in EC1456 trial expenses; a decrease of $0.5 million in compensation expense as a result of employee terminations since March 31, 2017, and a decrease of $0.4 million in manufacturing expense for EC1169 and EC1456. These decreases were partially offset by: an increase of $0.8 million in expenses related to development of PSMA-617; and an increase of $0.2 million related to our CAR T-cell therapy program.

General and administrative expenses were $3.8 million for the first quarter of 2018, which were consistent with the $3.7 million of expenses for the same period in 2017.

Cash, cash equivalents and investments were $173.1 million at Mar. 31, 2018, compared to $127.6 million at Mar. 31, 2017, and $97.5 million at Dec. 31, 2017. Cash, cash equivalents and investments of $173.1 million at Mar. 31, 2018 included $80.9 million of net proceeds from our public offering of 20,535,714 shares of our common stock that closed in March 2018.

Financial Expectations

The company anticipates its cash, cash equivalents and investments balance at the end of 2018 to exceed $130 million. Based on current operational assumptions, Endocyte has sufficient cash to fund its activities through the expected end of the VISION trial and potential proof of concept of its EC17/CAR T-cell therapy.

Conference Call

Endocyte management will host a conference call today at 8:30 a.m. EDT.

U.S. and Canadian participants: International:   (877) 845-0711 (760) 298-5081
     

A live, listen-only webcast of the conference call may be accessed by visiting the Investors & News section of the Endocyte website, www.endocyte.com .

The webcast will be recorded and available on the company's website for 90 days following the call.

Website Information Endocyte routinely posts important information for investors on its website, www.endocyte.com , in the “Investors & News” section. Endocyte uses this website as a means of disclosing material information in compliance with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the “Investors & News” section of Endocyte’s website, in addition to following its press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Endocyte’s website is not incorporated by reference into, and is not a part of, this document.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177 Lu-PSMA-617, entering phase 3 for metastatic castration-resistant prostate cancer (mCRPC). Endocyte also expects to have an Investigational New Drug application submitted in the fourth quarter of 2018 for its adaptor-controlled CAR T-cell therapy which will be initially studied in osteosarcoma. For additional information, please visit Endocyte's website at www.endocyte.com .

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to future spending, future cash balances, future use of capital, sufficiency of cash, the timing of initiation, interim assessments and completion of clinical trials, the enrollment period for, and availability and reporting of data from, ongoing and future clinical trials, the occurrence and timing of actions by regulatory agencies, estimates of the potential market opportunity for the company’s product candidates, and the company's future development plans including those relating to the completion of pre-clinical development in preparation for possible future clinical trials and future sources of supply of product candidates to support clinical and commercial activities. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company or independent investigators may experience delays in the initiation or completion of clinical trials (whether caused by competition, adverse events, patient enrollment rates, shortage of clinical trial materials, regulatory issues or other factors); risks that suppliers or other third party contractors may not fulfill their contractual obligations on a timely basis or at all;  risks that data from prior clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates; risks that early stage pre-clinical data may not be indicative of subsequent data when expanded to additional pre-clinical models or to subsequent clinical data; risks that evolving competitive activity and intellectual property landscape may impair the company's ability to capture value for the technology; risks that expectations and estimates turn out to be incorrect, including estimates of the potential markets for the company’s product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected future revenues, operations, expenditures and cash position. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com

Endocyte, Inc. Statements of Operations (dollars in thousands, except per share amounts) (unaudited)

  For the Three Months Ended March 31,  
  2017     2018  
               
Collaboration revenue $ 12     $ 16  
Costs and expenses:              
Research and development   7,994       5,255  
General and administrative   3,745       3,778  
Total costs and expenses   11,739       9,033  
Loss from operations   (11,727 )      (9,017 )
               
Interest income, net   235       413  
Other income, net   3       1  
Net loss $ (11,489 )    $ (8,603 )
               
Net loss per share - basic and diluted $ (0.27 )   $ (0.16 )
               
Comprehensive loss $ (11,501 )   $ (8,617 )
               
Weighted average number of common shares used in net loss per share – basic and diluted:   42,434,709       55,000,743  
               

Endocyte, Inc. Balance Sheets (in thousands)

    As of December 31,     As of March 31,  
    2017     2018  
          (unaudited)  
Assets                
Cash, cash equivalents and investments   $ 97,471     $ 173,125  
Other assets     3,291       3,553  
Total assets   $ 100,762     $ 176,678  
                 
Liabilities and stockholders’ equity                
Current liabilities   $ 4,546     $ 4,613  
Deferred revenue and other liabilities, net of current portion     732       363  
Total stockholders’ equity     95,484       171,702  
Total liabilities and stockholders’ equity   $ 100,762     $ 176,678  
                 
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 45

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 327

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Arbor Realty Trust Faces Securities Fraud Allegations

Updated Category News Views 108

Securities Lawsuit Against Arbor Realty Trust Looms Well, here we go again. Another day, another securities lawsuit hitting the headlines. This time it's Arbor Realty Trust (NYSE: ABR) getting caught in the crossfire, accused of pulling the wool over investors' eyes. Seems like 'truth in advertising' is just part of the PR playbook for some big shots. Understanding the...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 110

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 17

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 226

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 0

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 179

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 124

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 268

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading

Top 5 Most Recently Viewed Articles

Inbank's Bond Offering Surpasses Expectations with High Demand

Updated Category News Views 193

Inbank's Successful Subordinated Bond Subscription Recently, Inbank wrapped up its public offering of subordinated bonds, marking a significant moment in the company's financial journey. The event attracted considerable attention, with an impressive 935 investors participating, ultimately subscribing to bonds worth a total of 21.6 million euros. This enthusiasm resulted...

Continue Reading
Investors Alert: Class Action Against Starbucks Corporation

Updated Category News Views 87

Class Action Filed Against Starbucks Corporation The Gross Law Firm is reaching out to investors of Starbucks Corporation (NASDAQ: SBUX) following significant financial announcements and issues raised concerning the company's recent performance. The Purpose Behind the Class Action This class action aims to provide shareholders who purchased SBUX stocks during the recently...

Continue Reading
Unlock Your Franchise Potential with Free UT Haslam Courses

Updated Category News Views 185

Revolutionizing Franchising Education The University of Tennessee's Haslam College of Business is proud to offer its franchising certification program without any fees, thanks to the generous support of successful entrepreneur Shelly Sun Berkowitz. As the founder and executive chairwoman of BrightStar Group Holdings Inc., Berkowitz brings invaluable experience to the...

Continue Reading
Ultra Maritime Launches New Facility to Enhance Naval Warfare Solutions

Updated Category News Views 257

Ultra Maritime Opens New Innovative Facility Today marks an exciting new chapter for Ultra Maritime as it inaugurates its latest integrated design and manufacturing center. This state-of-the-art facility is dedicated to supporting the evolving needs of global allied navies, particularly in anti-submarine warfare (ASW). The center, located in Greenford, UK, offers a modern...

Continue Reading
Exciting New Fundraising Initiative by Robin Hood for NYC

Updated Category News Views 395

Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...

Continue Reading